Disease & disorder
Prader-Willi syndrome
MONDO:0008300
Prader-Willi syndrome is a rare genetic disorder characterized by hypothalamic-pituitary abnormalities with severe hypotonia during the neonatal period and first two years of life and the onset of hyperphagia with a risk of morbid obesity during infancy and adulthood, learning difficulties and behavioral problems or severe psychiatric problems.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
Loading mapped interventions…
MONDO disease family
Loading verified ontology relationships…
Recruiting studies by city
Loading research-site locations…
Trial status
Loading…
Trial phase
Loading…
Study start year
Loading…
Investigated drug interventions
Loading…
Clinical trials
40 shownRegulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion DysregulationNCT07607730 · 2027-01-01
RECRUITINGA Study of CSTI-500 in Patients With Prader-Willi SyndromeNCT07348601 · 2026-05-01
RECRUITINGTirzepatide in PWS, HO and GNSONCT06901245 · 2025-05-01
RECRUITINGAutistic Symptomatology and Sensory Profile in Children With Prader-Willi SyndromeNCT06877715 · 2025-04-07
RECRUITINGPhysical Activity and Community EmPOWERment ProjectNCT06740162 · 2025-01-10
RECRUITINGInstitutional Registry of Rare DiseasesNCT06573723 · 2024-07-01
RECRUITINGA Study of Pitolisant in Patients With Prader-Willi SyndromeNCT06366464 · 2024-05-28
RECRUITINGA Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway ImpairmentNCT06239116 · 2024-03-05
RECRUITINGEffects of Transcutaneous Vagus Nerve Stimulation on Emotion Regulation and Executive Functioning in Prader-Willi SyndromeNCT06720571 · 2023-11-22
RECRUITINGCerebellar TMS and Satiety in Prader-Willi SyndromeNCT05938543 · 2023-09-01
RECRUITINGThe Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and ProbioticsNCT05791604 · 2023-04-01
RECRUITINGGROWing Up With Rare GENEtic SyndromesNCT04463316 · 2018-10-01
RECRUITINGIDMet (RaDiCo Cohort) (RaDiCo-IDMet)NCT05945576 · 2017-03-10
RECRUITINGRegister of Patients With Prader-Willi SyndromeNCT02829684 · 2009-03-01
RECRUITINGA 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.NCT07266324 · 2026-01-01
NOT_YET_RECRUITINGObservational Study of VYKAT™ XR in Patients With Prader-Willi SyndromeNCT07450664 · 2025-11-26
ENROLLING_BY_INVITATIONA Study of Pitolisant in Participants With Prader-Willi SyndromeNCT07219485 · 2025-08-20
ENROLLING_BY_INVITATIONBrain Olfactory Pathways in Prader-Willi SyndromeNCT07006207 · 2025-06-23
NOT_YET_RECRUITINGA Study of Setmelanotide in Patients With Prader-Willi SyndromeNCT06772597 · 2025-03-04
ACTIVE_NOT_RECRUITINGARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective TrialNCT06828861 · 2024-12-20
TERMINATEDThe Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) TrialNCT07197034 · 2024-07-23
TERMINATEDAdolescent Projections During Transition in Prader-Willi SyndromeNCT06279052 · 2024-03-01
UNKNOWNRespiratory Restriction in Prader-Willi SyndromeNCT06851351 · 2024-01-16
COMPLETEDA Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWSNCT06144645 · 2024-01-08
ACTIVE_NOT_RECRUITINGImpact of Bright Light Therapy on Prader-Willi SyndromeNCT05939453 · 2023-10-01
ACTIVE_NOT_RECRUITINGAn Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)NCT05879614 · 2023-09-01
WITHDRAWNMitochondrial Complex I Dysfunction in PWSNCT03831425 · 2023-06-01
WITHDRAWNEvaluation of the Psychological Profile of Adult Patients With Prader-Willi SyndromeNCT06295315 · 2023-04-21
COMPLETEDDevelopment of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi SyndromeNCT05783791 · 2023-04-20
COMPLETEDGrowth Hormone Study in Adults With Prader-Willi SyndromeNCT04484051 · 2023-03-24
UNKNOWNOpen-Label Extension Study of DCCR in Patients With Prader-Willi SyndromeNCT05701774 · 2023-01-31
ACTIVE_NOT_RECRUITINGUnderstanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi SyndromeNCT05541003 · 2023-01-06
COMPLETEDA Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi SyndromeNCT05387798 · 2023-01-01
WITHDRAWNA Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi SyndromeNCT05504395 · 2022-11-14
COMPLETEDUltrasound to Assess Sarcopenia in Prader Willi SyndromeNCT06448871 · 2022-10-17
COMPLETEDStudy to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi SyndromeNCT05322096 · 2022-09-22
COMPLETEDA Study of Oral ARD-101 in Patients With Prader-Willi SyndromeNCT05153434 · 2022-05-27
COMPLETEDBiological Age Assessment in Adults With Prader-Willi Syndrome (ETABIOLPWS)NCT05778032 · 2022-05-25
ACTIVE_NOT_RECRUITINGCharacterization of Serum Proteome in Subjects With Prader Willi Syndrome (PROTEOMARKER)NCT05761184 · 2022-04-28
COMPLETEDA Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi SyndromeNCT05098509 · 2022-04-13
TERMINATEDDrugs being studied
Research locations
NashvilleTennessee, United States20ToulouseFrance19GainesvilleFlorida, United States17San DiegoCalifornia, United States16AuroraColorado, United States10BostonMassachusetts, United States10Kansas CityKansas, United States10AtlantaGeorgia, United States9ParisFrance9Salt Lake CityUtah, United States9SeattleWashington, United States9BrooklynNew York, United States8
Leading sponsors
University Hospital, Toulouse15Samsung Medical Center6Soleno Therapeutics, Inc.6Istituto Auxologico Italiano4Radius Pharmaceuticals, Inc.4Aardvark Therapeutics, Inc.3Assistance Publique - Hôpitaux de Paris3Children's Mercy Hospital Kansas City3Harmony Biosciences Management, Inc.3Rhythm Pharmaceuticals, Inc.3The Hospital for Sick Children3University of Florida3ConSynance Therapeutics2Corporacion Parc Tauli2Duke University2
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.